Examining adjuvant radiation dose in head and neck squamous cell carcinoma.
Publication/Presentation Date
7-1-2019
Abstract
BACKGROUND: Compare adjuvant radiation dose trends and outcomes in head and neck squamous cell carcinoma (HNSCC).
METHODS: Nonmetastatic HNSCCs treated between 2004 and 2014 with primary site surgery, lymph node dissection, and adjuvant radiation were identified in the National Cancer Database. Standard dose radiation (SD-RT) was defined as an equivalent dose in 2 Gy (EQD2) ≥56.64 and ≤60 Gy and high-dose radiation (HD-RT) as an EQD2 >60 and < 70 Gy.
RESULTS: HD-RT was given to 46% of the 15 836 HNSCC patients managed with adjuvant radiation. When adjusted for poor prognostic factors, HD-RT was associated with increased mortality (HR1.09; 95%CI 1.02-1.16). In nonoropharynx or human papillomavirus-negative oropharynx primary that had positive margins, ≥5 positive lymph nodes, and/or extranodal extension, HD-RT was still not associated with improved survival (HR 1.01, 95% CI 0.91-1.12).
CONCLUSIONS: There was no survival benefit from postoperative dose escalation above EQD2 60 Gy even in a high-risk cohort.
Volume
41
Issue
7
First Page
2133
Last Page
2142
ISSN
1097-0347
Published In/Presented At
Avkshtol, V., Handorf, E. A., Ridge, J. A., Leachman, B. K., Liu, J. C., Bauman, J., & Galloway, T. J. (2019). Examining adjuvant radiation dose in head and neck squamous cell carcinoma. Head & neck, 41(7), 2133–2142. https://doi.org/10.1002/hed.25680
Disciplines
Medicine and Health Sciences
PubMedID
30737968
Department(s)
Department of Surgery
Document Type
Article